🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very excited to be partnering with the SynGAP Research Fund (SRF) team + @rarebasepbc in our efforts to accelerate treatments for #syngap1 and many other rare genetic diseases. Let’s go! 🚀#raredisease

Good luck to the #CannonballForACure team as they raise funds for #SYNGAP1 research! Our co-founders Onno Faber and Omid Karkouti will call in to the livestream tomorrow at 11am PST -- join here: youtu.be/rK8CRsiKpdk 🛣️🧬🚀

Congratulations to the #CannonballRun team -- they completed 2,906 miles in 2 days 9hrs & raised over $112k to fund #SYNGAP1 research! Read more below.

Last week our Co-Founder and CEO Onno Faber presented on "Precision Medicine for Rare Genetic Diseases" at the Rare Entrepreneur Bootcamp hosted by Ultragenyx. As always, this event serves as a reminder of the power of collaboration as we search for solutions for rare diseases.

We are honored at @rarebasepbc to be working with so many patient communities to create a path forward to find therapies for rare genetic diseases. Thanks to HOPE4HARPER (hope4harper.com) for enabling our work on #CDKL5 related disorders.

“These things don’t have to be lonely crusades, but they are. Everyone is on their own right now.” Onno Faber and @rarebasepbc are a mission to remake the dysfunctional rare disease research space. buff.ly/3CoXeuP

Happy Holidays from all of us here at Rarebase! Thank you to all of our collaborators for your trust and support. We’re entering the new year with hope and excitement, and together we will relentlessly continue to create a path forward for people affected by rare disease. 🚀

Clayton Mellina (Clayton Mellina), our Director of Software Engineering, uses breakthrough technologies to drive precision medicine research for rare diseases. Learn more about engineering and AI in the biotech space in our latest episode of Rarebase Remarks: spotifyanchor-web.app.link/e/egNvp1Jfswb

“These things don’t have to be lonely crusades, but they are. Everyone is on their own right now.” Onno Faber and @rarebasepbc are a mission to remake the dysfunctional rare disease research space. buff.ly/3CoXeuP

"Life's most persistent and urgent question is, 'What are you doing for others?’” It’s a simple and profound idea from Dr. Martin Luther King, Jr., that inspires and motivates me this #MLK day.

Next week our CSO, Chris Moxham, PhD, will give a showcase talk titled “Accelerating a Path Forward for #RareDisease #DrugDiscovery” Precision Medicine World Conference on January 27, 2023 in Santa Clara, CA. We are excited to share our insights on scalable approaches for precision medicine #PMWC23

Our #precisionmedicine platform Function identifies #drugrepurposing candidates that have the potential to target the root cause biology of rare genetic diseases. Discover how we identify these candidates based on common types of genetic variants: rarebase.org/post/how-does-…

Honored to be working with SynGAP Research Fund (SRF) on drug discovery for SYNGAP1 related disorders with @rarebasepbc. Thanks Mike Graglia 🌻 and Ashley S. Evans for all you do for the community!

Tomorrow is International Day of Women and Girls in Science 🧬🔬🚀 We are grateful to all the women on the Rarebase team for your tireless work to foster partnerships with patient organizations and drive our precision medicine research forward for the #raredisease community.

Wonderful & strange to look at the neurons of my two sons👨‍👨‍👦‍👦 (#SYNGAP1🧬 Variant & Wild Type) side by side on a plate. Thank you @rarebasepbc, Onno Faber, Omid Karkouti & SynGAP Research Fund (SRF) for making this possible. Three more lines to go! 💊#Repurposing #RareDiseases #TherapiesNow

“These things don’t have to be lonely crusades, but they are. Everyone is on their own right now.” Onno Faber and @rarebasepbc are a mission to remake the dysfunctional rare disease research space. #RareDiseaseDay #RareDiseaseDay2023 neo.life/2021/09/the-ch…

Neurodevelopmental disorders make up 77% of our current drug discovery portfolio. This National Developmental Disabilities Awareness Month, let's champion support & inclusion for affected individuals with the rare disease community. #DDAM2023

We were honored to invite Ashlee Vance to Transcripta Bio to share our story and how we are charting a faster path in drug discovery to create better lives for people around the world. bloomberg.com/news/articles/…

Characterizing collections of molecules is an important chemoinformatics task. Beyond annotating molecules by common descriptors, can we gain insight by leveraging LLMs for initial triage? Our prototype app, MolSifter, does just that!

🌟 An update on our exciting progress in learning and predicting the effects of small molecules on the transcriptome! 🌟 transcriptabio.com/post/mastering…